VIDEO: Ruxolitinib plus navitoclax yields ‘challenging’ results in myelofibrosis
Click Here to Manage Email Alerts
In this video, John Mascarenhas, MD, discussed the TRANSFORM-1 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.
Mascarenhas, professor of medicine at the Icahn School of Medicine at Mount Sinai, discussed the study, which examined a combination of ruxolitinib plus navitoclax into high-risk myelofibrosis, which yielded unclear results about the combination’s future as a front-line therapy.
“If you look at the toxicity, there was more grade three, four thrombocytopenia that was likely driving dose modifications that ultimately would compromise efficacy. So this is an approach that unfortunately in the first line setting, I think will be challenging to take forward as an approved drug,” Mascarenhas said.
Collapse
Read more about
Click Here to Manage Email Alerts